Clinical Trial
Evaluation of lorcainide, a new anti-arrhythmic agent
- PMID: 7302777
Item in Clipboard
Clinical Trial
Evaluation of lorcainide, a new anti-arrhythmic agent
S Afr Med J.
.
Abstract
A new anti-arrhythmic agent, lorcainide, has been compared with lignocaine in patients with acute myocardial infarction. Lorcainide has been shown to be as effective as lignocaine in suppressing ventricular ectopy. Lorcainide is unusually free of side-effects and has the great advantage over lignocaine of being effective when given orally.
Similar articles
-
Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.Drugs. 1984 Apr;27(4):279-300. doi: 10.2165/00003495-198427040-00001. Drugs. 1984. PMID: 6373222 Review.
-
Lorcainide in the prophylaxis of ventricular arrhythmias in acute myocardial infarction.Ann Clin Res. 1984;16(1):18-22. Ann Clin Res. 1984. PMID: 6378045 Clinical Trial.
-
Antiarrhythmic effect of lorcainide during chronic treatment.Arzneimittelforschung. 1980;30(9):1593-5. Arzneimittelforschung. 1980. PMID: 7193031
-
[Preliminary clinical and experimental data on a new anti-arrhythmic drug: lorcainide].Minerva Med. 1980 Apr 2;71(13):975-80. Minerva Med. 1980. PMID: 7375011 Italian.
-
Lorcainide (R 15 889), a first review.Acta Cardiol. 1981;36(3):207-34. Acta Cardiol. 1981. PMID: 7020313 Review.
Cited by
-
Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.Drugs. 1984 Apr;27(4):279-300. doi: 10.2165/00003495-198427040-00001. Drugs. 1984. PMID: 6373222 Review.